logo
Plus   Neg
Share
Email

Stock Alert: American Outdoor Brands Down 38%

Shares of American Outdoor Brands Corporation (AOBC) are tanking more than 38% after the firearm maker's third-quarter earnings and revenue missed estimates. Fourth-quarter and full-year outlook also remains lower than the Street estimates.

Third-quarter net income was $5.7 million, or $0.10 per share, compared with net loss of $5.7 million, or $0.10 per share, for the comparable quarter last year. Excluding items, EPS was $0.13 compared with $0.16 last year. On average, 5 analysts polled by Thomson Reuters were expecting earnings of $0.23 per share.

Quarterly net sales edged up to $166.7 million from $162.0 million for the third quarter last year.

For the fourth quarter, the company sees revenue in the range of $205 million - $215 million and EPS of $0.33- $0.37. Analysts see earnings of $0.45 per share on revenue of $224.32 million for the quarter.

For the full year, revenue is expected in the range of $650 million - $660 million and EPS in the range of $0.58- $0.62. The consensus estimate for EPS is at $0.81 on revenue of $689.65 million.

During the last 52-weeks, AOBC has traded in the range of $5.41- $11.43 and is currently at $6.47.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hyundai Motor has launched a new IONIQ brand dedicated to battery electric vehicles, as the automaker is accelerating its efforts to gain a share in the fast-growing global EV market. Under the IONIQ brand, Hyundai plans to introduce three new dedicated electric vehicle models over the next four years. Hyundai is South Korea's largest automaker. Amazon.com, Inc. is in talks with mall operator Simon Property Group, Inc. to use the abandoned anchor departmental stores of JC Penny and Sears at their malls as fulfillment centers, reports said. This is expected to help the e-commerce giant in boosting their last mile delivery, which is the last leg of the delivery process. The U.S. Food and Drug Administration announced the approval of Trevena Inc.'s Olinvyk (oliceridine), a new opioid for intravenous use in hospitals or other controlled clinical settings. Olinvyk is an opioid agonist to manage moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate.
Follow RTT